Post-approval studies (Phase 4)Study completedNCT00718536
What this trial is testing
Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy
Who this might be right for
HIV Infections
Germans Trias i Pujol Hospital 15